Form 4: Organon Interim CEO Morrissey Reports Stock Transactions

Interim CEO Joseph T. Morrissey Jr. reported the vesting of restricted stock units and a new grant of 333,889 units in Organon & Co.

Summary

• Interim CEO Joseph T. Morrissey Jr. acquired 24,584 shares of common stock through the vesting of restricted stock units (RSUs) on March 31, 2026.
• A total of 7,005 shares were withheld by the company to satisfy tax obligations at a price of $5.70 per share.
• The reporting person was granted a new award of 333,889 RSUs, which will vest in three equal annual installments starting March 31, 2027.
• Following these transactions, the reporting person holds 123,122.923 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation and standard equity vesting.

Positives

• The executive maintains a significant direct equity stake of 123,122.923 shares, aligning interests with shareholders.
• The new RSU grant incentivizes long-term retention and performance through a three-year vesting schedule.

Negatives

• The company withheld 7,005 shares to cover tax liabilities associated with the vesting of equity awards.

Risks

• The value of the equity compensation is subject to market volatility, as evidenced by the $5.70 per share valuation used for tax withholding.

Future Outlook

The newly granted 333,889 RSUs are scheduled to vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029, contingent upon continued service.

Industry Context

StockSavvy.ai notes that executive equity vesting and tax withholding are standard corporate governance practices in the pharmaceutical sector, reflecting routine compensation management rather than a change in strategic direction.

Comparison to Industry Standards

• The use of RSUs as a primary long-term incentive vehicle is consistent with compensation structures at peer pharmaceutical companies like Viatris or Pfizer.
• The three-year graded vesting schedule aligns with standard industry practices for executive retention.

Stakeholder Impact

• Shareholders may view the continued equity-based compensation of the Interim CEO as a mechanism to ensure alignment with long-term company performance.

Next Steps

• Vesting of the first installment of the new RSU grant on March 31, 2027.

Key Dates

Keywords

Organon, OGN, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units